论文部分内容阅读
肝移植术后乙肝病毒再感染可能会引起肝细胞癌复发,应用乙肝免疫球蛋白(HBIG)及核苷(酸)类似物联合治疗可降低肝移植术后乙肝复发率。本研究回顾性分析了1985年1月至2010年12月美国7个移植中心的肝移植病例,检测乙肝病毒、肝细胞癌(HCC)与患者生存率间的关系。本研究依据抗乙肝病毒治疗策略的变迁将患者分为3个年代组(1985—1994年,1995—2004年和2005—2010年),选取了16个变量,分析其是否与患者生存率和肝细胞癌复发相关。本研究共纳入因乙肝相关疾病接受肝移植
Hepatitis B virus re-infection after liver transplantation may cause recurrence of hepatocellular carcinoma. The combination of hepatitis B immunoglobulin (HBIG) and nucleoside (acid) analogues can reduce the recurrence rate of hepatitis B after liver transplantation. This study retrospectively analyzed the cases of liver transplantation from January 1985 to December 2010 in seven transplant centers in the United States and examined the relationship between hepatitis B virus, hepatocellular carcinoma (HCC) and patient survival. In this study, we divided the patients into three age groups (1985-1994, 1995-2004 and 2005-2010) according to the change of anti-hepatitis B virus treatment strategy. We selected 16 variables and analyzed whether they were related to the survival rate of patients and liver Recurrence of cell carcinoma. This study enrolled a liver transplant due to hepatitis B related diseases